NASDAQ : BBTX
Bambusa Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | 2025-12-31 | 2024-12-31 | |
|---|---|---|---|
| Selling, General & Admin | 5.91M | 855.00K | |
| Research & Development | 38.10M | 13.03M | |
| Other Operating Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 44.01M | 13.88M | |
| Operating Income | -52.62M | -44.01M | -13.88M |
| Interest Expense (Income) | -2.75M | -2.17M | -131.00K |
| Other Expense (Income) | -3.74M | -2.98M | -8.00K |
| Pretax Income | -46.13M | -37.10M | -13.74M |
| Income Tax | 2.58M | 2.23M | |
| Net Income | -48.70M | -41.09M | -13.74M |
| Net Income Common | -48.70M | -39.33M | |
| Free Cash Flow | -40.90M | -39.80M | -4.63M |
| EBITDA | -48.88M | -41.02M | -13.87M |
| EBIT | -48.88M | -41.02M | -13.87M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | 2025-12-31 | 2024-12-31 | |
|---|---|---|---|
| Cash & Equivalents | 46.53M | 50.64M | 9.36M |
| Short-Term Investments | 24.94M | 39.98M | |
| Cash & Cash Equivalents | 71.47M | 90.63M | 9.36M |
| Other Current Assets | 3.82M | 3.50M | 402.00K |
| Total Current Assets | 75.30M | 94.13M | 9.76M |
| Other Long-Term Assets | 1.58M | 0.00 | |
| Total Long-Term Assets | 1.58M | 0.00 | |
| Total Assets | 95.71M | 9.76M | |
| Accounts Payable | 1.91M | 13.00K | |
| Other Current Liabilities | 12.22M | 7.74M | 9.30M |
| Total Current Liabilities | 12.22M | 9.65M | 9.32M |
| Other Long-Term Liabilities | 0.00 | 0.00 | |
| Total Long-Term Liabilities | 0.00 | 0.00 | |
| Total Liabilities | 9.65M | 9.32M | |
| Retained Earnings | -54.83M | -13.74M | |
| Comprehensive Income | 60.00K | ||
| Shareholders' Equity | -70.96M | -49.17M | -13.55M |
| Total Debt | 0.00 | 0.00 | |
| Net Cash (Debt) | 71.47M | 90.63M | 9.36M |
| Working Capital | 63.08M | 84.48M | 448.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | 2025-12-31 | 2024-12-31 | |
|---|---|---|---|
| Net Income | -48.70M | -39.33M | |
| Share-Based Compensation | 5.38M | 193.00K | |
| Other Operating Activities | 7.80M | -4.09M | 8.91M |
| Operating Cash Flow | -40.90M | -39.80M | -4.63M |
| Change in Investments | -39.73M | ||
| Investing Cash Flow | -24.70M | -39.73M | |
| Share Issuance / Repurchase | 120.81M | 14.00M | |
| Financing Cash Flow | 33.02M | 120.81M | 14.00M |
| Net Cash Flow | -32.58M | 41.28M | 9.36M |
| Free Cash Flow | -40.90M | -39.80M | -4.63M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | 2025-12-31 | 2024-12-31 | |
|---|---|---|---|
| Market Capitalization | 763.63M | ||
| Enterprise Value | 692.15M | ||
| Net Debt / Equity Ratio | 1.84 | 0.69 | |
| Quick Ratio | 5.85 | 9.39 | 1.00 |
| Return on Assets (ROA) | -42.93% | -140.73% | |
| Return on Invested Capital (ROIC) | -101.73% | -3,098.21% | |
| Return on Capital Employed (ROCE) | 399.86% | -47.67% | -3,096.43% |